INDAPTUS THERAPEUTICS INC (INDP)

US45339J1051 - Common Stock

0.8891  -0.05 (-5.21%)

After market: 0.91 +0.02 (+2.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INDP. INDP was compared to 565 industry peers in the Biotechnology industry. The financial health of INDP is average, but there are quite some concerns on its profitability. INDP has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

INDP had negative earnings in the past year.
In the past year INDP has reported a negative cash flow from operations.
In the past 5 years INDP always reported negative net income.
In the past 5 years INDP always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -180.75%, INDP is doing worse than 88.79% of the companies in the same industry.
The Return On Equity of INDP (-248.09%) is worse than 71.17% of its industry peers.
Industry RankSector Rank
ROA -180.75%
ROE -248.09%
ROIC N/A
ROA(3y)-57.79%
ROA(5y)-92.93%
ROE(3y)-69.11%
ROE(5y)-143.41%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

INDP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

INDP has about the same amout of shares outstanding than it did 1 year ago.
INDP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

INDP has an Altman-Z score of -11.92. This is a bad value and indicates that INDP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INDP (-11.92) is worse than 78.47% of its industry peers.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.92
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

INDP has a Current Ratio of 3.42. This indicates that INDP is financially healthy and has no problem in meeting its short term obligations.
INDP has a Current ratio of 3.42. This is comparable to the rest of the industry: INDP outperforms 41.46% of its industry peers.
A Quick Ratio of 3.42 indicates that INDP has no problem at all paying its short term obligations.
The Quick ratio of INDP (3.42) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42

More info and screens

1

3. Growth

3.1 Past

INDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.97%.
EPS 1Y (TTM)4.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.24%
EPS Next 2Y18.4%
EPS Next 3Y18.23%
EPS Next 5Y17.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INDP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as INDP's earnings are expected to grow with 18.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.4%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (12/23/2024, 8:12:26 PM)

After market: 0.91 +0.02 (+2.35%)

0.8891

-0.05 (-5.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners5.88%
Inst Owner Change0.85%
Ins Owners26.67%
Ins Owner Change40.08%
Market Cap10.68M
Analysts82.5
Price Target8.67 (875.14%)
Short Float %0.99%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.96%
Min EPS beat(2)14.67%
Max EPS beat(2)33.25%
EPS beat(4)4
Avg EPS beat(4)20.84%
Min EPS beat(4)12.85%
Max EPS beat(4)33.25%
EPS beat(8)8
Avg EPS beat(8)20.75%
EPS beat(12)12
Avg EPS beat(12)26.83%
EPS beat(16)13
Avg EPS beat(16)12.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15%
PT rev (3m)-15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.41%
EPS NY rev (1m)11.14%
EPS NY rev (3m)9.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -180.75%
ROE -248.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.79%
ROA(5y)-92.93%
ROE(3y)-69.11%
ROE(5y)-143.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -11.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
EPS Next Y3.24%
EPS Next 2Y18.4%
EPS Next 3Y18.23%
EPS Next 5Y17.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.97%
OCF growth 3YN/A
OCF growth 5YN/A